AbbVie Inc. $ABBV Stock Holdings Reduced by Cornerstone Capital Inc.

Cornerstone Capital Inc. cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,329 shares of the company’s stock after selling 3,427 shares during the period. AbbVie accounts for about 3.5% of Cornerstone Capital Inc.’s portfolio, making the stock its 8th largest position. Cornerstone Capital Inc.’s holdings in AbbVie were worth $39,586,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. State Street Corp raised its holdings in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after buying an additional 23,991,451 shares during the period. Corient Private Wealth LP acquired a new stake in shares of AbbVie during the second quarter worth $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of AbbVie during the second quarter valued at $2,905,952,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the topic of several research reports. Barclays upped their target price on AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research report on Monday. Piper Sandler lifted their price target on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Canaccord Genuity Group lifted their price target on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Argus boosted their price target on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $275.00 price target on shares of AbbVie in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $297.85.

Check Out Our Latest Stock Report on AbbVie

AbbVie Trading Down 0.3%

ABBV opened at $294.18 on Tuesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93. The firm has a 50 day moving average of $276.27 and a two-hundred day moving average of $241.28. The firm has a market capitalization of $520.00 billion, a PE ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.86 EPS. As a group, analysts predict that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s dividend payout ratio is 125.30%.

Insider Transactions at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.

AbbVie Company Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.